Publications
20
Citations
89
Est. group size
~11
Recurring co-author estimate
Active years
7
Publishing since 2020
Lotus Neidemire-Colley's research focuses on complications following blood stem cell (hematopoietic) transplants, particularly graft-versus-host disease (GVHD), where donor immune cells attack the recipient's tissues. Their work uses gene-editing tools like CRISPR/Cas9 to study and target T cells, along with biomarkers and endothelial cell biology, to better understand and prevent transplant-related complications. Much of this research is conducted through multi-institution consortia studying outcomes after allogeneic (donor-derived) transplants.
Publication output has grown from none in the early part of the decade to a steady pace of 2-4 papers per year since 2020.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Soluble Fms-like Tyrosine Kinase-1 (sFlt-1) As a Clinical Biomarker for Individual Susceptibility to Post-Transplant Complications: A Report from the MIDAS Consortium.
Transplantation and Cellular Therapy · 2025
- Pre-HCT creatinine defines sex-specific risk for severe TMA after allogeneic transplantation: A report from the MIDAS consortium.
Blood · 2025
- CRISPR/Cas9 deletion of MIR155HG in human T cells reduces incidence and severity of acute GVHD in a xenogeneic model
Blood Advances · 2024
- Epidermal growth factor-like 7 is a novel therapeutic target in mantle cell lymphoma
Experimental Hematology · 2023
- Corrigendum: Role of endothelial cells in graft-versus-host disease
Frontiers in Immunology · 2023
- CRISPR/Cas9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease
The Journal of Immunology · 2023
- Prohibitin is Upregulated on Donor T cells in Murine Acute Graft-versus-Host Disease and Promotes Th17 Response
The Journal of Immunology · 2023
- Role of endothelial cells in graft-versus-host disease
Frontiers in Immunology · 2022
- CRISPR/CAS9 Gene Editing of MIR155HG in Primary Human T Cells to Prevent Acute Graft-Versus-Host Disease
Blood · 2022
- Abstract 2335: DHODH inhibition modulates T cell metabolism reducing GVHD and prevents relapse following allogeneic HCT
Cancer Research · 2022
- Prohibitin Is a Substrate of PRMT5 in T Cells and Is a Potential Therapeutic Target for Acute Graft-Versus-Host Disease
Blood · 2022
- Blood×7
- The Journal of Immunology×4
- Frontiers in Immunology×2
- Transplantation and Cellular Therapy×2
- JCI Insight×1
- Sumithira Vasu
Medicine · The Ohio State University
- Brandon M. Triplett
Medicine · Purdue University West Lafayette
- Justin Tossey
Medicine · The Ohio State University
- Julianna Roddy
Medicine · The Ohio State University
- Qiuhong Zhao
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile